文献速递皮肤肿瘤

验证表皮AMBRA1与loricrin(AMBLor)作为非溃疡性AJCC I/II期皮肤黑色素瘤预后生物标志物

Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for nonulcerated American Joint Committee on Cancer stage I/II cutaneous melanoma.
PubMed 文献 · Br J Dermatol · 2024-01-01

研究在发现队列(n=540)和验证队列(n=300)中,用自动免疫组化分析非溃疡性AJCC I/II期黑色素瘤瘤周表皮AMBRA1与loricrin联合表达(AMBLor)。AMBLor低风险组无复发生存率在发现队列为95.5% vs 81.7%(P<0.001),验证队列为97.6% vs 78.3%(P<0.001);合并队列多变量分析风险比3.469(95%CI 1.403-8.580,P=0.007),总体阴性预测值96.5%。

要点

  • AMBLor低风险组无复发生存率显著高于高风险组(发现队列95.5% vs 81.7%,验证队列97.6% vs 78.3%)。
  • 合并队列中AMBLor的估计效应有统计学意义,风险比3.469(95%CI 1.403-8.580,P=0.007)。
  • AMBLor总体阴性预测值为96.5%,可用于识别复发低风险的非溃疡性I/II期黑色素瘤。

核心结论

  • 数据进一步验证AMBLor可作为预后生物标志物,识别非溃疡性AJCC I和II期黑色素瘤中复发低风险的肿瘤。

研究设计与样本

  • 采用自动免疫组化分析地理上不同的发现队列(n=540)和验证队列(n=300)中非溃疡性AJCC I和II期黑色素瘤的瘤周表皮AMBRA1与loricrin表达。
  • AMBLor状态分别与发现队列、验证队列及合并队列的临床结局进行相关性分析。

主要发现

  • 发现队列中AMBLor低风险组无复发生存率为95.5%,高风险组为81.7%(多变量log-rank检验,P<0.001),阴性预测值为96.0%。
  • 验证队列中AMBLor低风险组无复发生存率为97.6%,高风险组为78.3%(多变量log-rank检验,P<0.001),阴性预测值为97.6%。
  • 合并队列多变量模型(考虑AMBLor、Breslow厚度、年龄和性别)显示AMBLor的估计效应有统计学意义,风险比3.469(95%置信区间1.403-8.580,P=0.007),总体阴性预测值为96.5%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combined expression of the autophagy-regulatory protein AMBRA1 (activating molecule in Beclin1-regulated autophagy) and the terminal differentiation marker loricrin in the peritumoral epidermis of stage I melanomas can identify tumour subsets at low risk of -metastasis. OBJECTIVES: To validate the combined expression of peritumoral AMBRA1 and loricrin (AMBLor) as a prognostic biomarker able to identify both stage I and II melanomas at low risk of tumour recurrence. METHODS: Automated immunohistochemistry was used to analyse peritumoral AMBRA1 and loricrin expression in geographically distinct discovery (n = 540) and validation (n = 300) cohorts of nonulcerated American Joint Committee on Cancer (AJCC) stage I and II melanomas. AMBLor status was correlated with clinical outcomes in the discovery and validation cohorts separately and combined. RESULTS: Analysis of AMBLor in the discovery cohort revealed a recurrence-free survival (RFS) rate of 95.5% in the AMBLor low-risk group vs. 81.7% in the AMBLor at-risk group (multivariate log-rank, P < 0.001) and a negative predictive value (NPV) of 96.0%. In the validation cohort, AMBLor analysis revealed a RFS rate of 97.6% in the AMBLor low-risk group vs. 78.3% in the at-risk group (multivariate log-rank, P < 0.001) and a NPV of 97.6%. In a multivariate model considering AMBLor, Breslow thickness, age and sex, analysis of the combined discovery and validation cohorts showed that the estimated effect of AMBLor was statistically significant, with a hazard ratio of 3.469 (95% confidence interval 1.403-8.580, P = 0.007) and an overall NPV of 96.5%. CONCLUSIONS: These data provide further evidence validating AMBLor as a prognostic biomarker to identify nonulcerated AJCC stage I and II melanoma tumours at low risk of disease recurrence.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Ewen T, Husain A, Stefanos N, et al. Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for nonulcerated American Joint Committee on Cancer stage I/II cutaneous melanoma. Br J Dermatol. 2024. PMID: 38006317. doi:10.1093/bjd/ljad459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。